The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
Abstract
PURPOSE AND METHODS: Associations between thromboembolism and malignancy, usually widespread, and between thromboembolism and hormonal and/or chemotherapy have been previously reported. We performed a randomized trial of tamoxifen 30 mg/d for 2 years (T) versus T plus 6 months of intravenous chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF) for postmenopausal women with involved axillary nodes and positive estrogen receptor (ER) or progesterone receptor (PgR) status following primary therapy for breast cancer. RESULTS: We observed one or more thromboembolic events in 48 of 353 women (13.6%) allocated to receive T plus CMF in comparison to five of 352 women (2.6%) randomized to receive T alone (P < .0001). Six women in the T plus CMF arm, but none randomized to receive T alone, suffered two thromboembolic events while an study therapy. There were also significantly more women who developed severe (grade 3 to 5) thromboembolic events in the T plus CMF arm than in the T arm (34 v five; P < .0001). Most thromboembolic events (39 of 54) occurred while women were actually receiving chemotherapy (P < .0001). Thromboembolic complications resulted in more days in hospital and more deaths than any other complication of therapy, including infection, in this trial. CONCLUSION: Thromboembolism related to the addition of CMF chemotherapy to tamoxifen as adjuvant therapy in this group of women represents a relatively common and serious complication that may outweigh any benefits offered by this additional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Self-citationDeep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer
Prandoni, P., Lensing, A. W. A., Büller, H. R., Cogo, A., Prins, M. H., Cattelan, A. M., Cuppini, S., Noventa, F., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210153271604 · Cited by 680
Levine, M., Hirsh, J., Arnold, A., Gent, M., Levine, M., Arnold, A., Bramwell, V., Pritchard, K. I., Stewart, D., Warr, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90008-6 · Cited by 510
Self-citationThe Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer
Levine, M. N., Gent, M., Hirsh, J., Arnold, A., Goodyear, M. D., Hryniuk, W., & De Pauw, S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198802183180703 · Cited by 412
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Fisher, B., Redmond, C., Legault-Poisson, S., Dimitrov, N. V., Brown, A. M., Wickerham, D. L., Wolmark, N., Margolese, R. G., Bowman, D., & Glass, A. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.6.1005 · Cited by 291
Vascular toxicity associated with antineoplastic agents.
Doll, D. C., Ringenberg, Q. S., & Yarbro, J. W. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.9.1405 · Cited by 250
Goodnough, L. T., Saito, H., Manni, A., Jones, P. K., & Pearson, O. H. (1984) · Cancer · doi:10.1002/1097-0142(19841001)54:7<1264::aid-cncr2820540706>3.0.co;2-r · Cited by 202
Fisher, B., Redmond, C. K., Wickerham, D. L., Bowman, D., Schipper, H., Wolmark, N., Sass, R., Fisher, E. R., Jochimsen, P. R., & Legault-Poisson, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.572 · Cited by 151
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Metadata
- Authors
- Pritchard, K. I., Paterson, A. H., Paul, N. A., Zee, B., Fine, S., & Pater, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1996-10
- Volume
- 14
- Issue
- 10
- Pages
- 2731-2737
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2228075402
- Cited by
- 269
- References
- 17
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. https://app.cochat.ai/papers/10.1200/jco.1996.14.10.2731
- The paper
- Pritchard, K. I., Paterson, A. H., Paul, N. A., Zee, B., Fine, S., & Pater, J. (1996). Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1996.14.10.2731
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.